Methods and materials for identifying and treating membranous nephropathy
US-2024353404-A1 · Oct 24, 2024 · US
Anti-pcsk9 antibodies, formulations, dosing, and methods of use
US2016355606A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2016355606-A1 |
| Application number | US-201514981853-A |
| Country | US |
| Kind code | A1 |
| Filing date | Dec 28, 2015 |
| Priority date | Jun 15, 2012 |
| Publication date | Dec 8, 2016 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The invention provides anti-PCSK9 antibodies, formulations, dosing regimens, and methods of using the same.
First claim
Opening claim text (preview).
1 . An anti-PCSK9 antibody comprising a heavy chain and light chain variable domain comprising six hypervariable region (HVR) sequences: (i) HVR-H1 comprising GFTFX 1 X 2 X 3 X 4 IH (SEQ ID NO:28), wherein X 1 is S or T; X 2 is G, R or S; X 3 is H, T or Y; X 4 is A or T; (ii) HVR-H2 comprising RISPANGNTNYADSVKG (SEQ ID NO:4); (iii) HVR-H3 comprising WIGSRELYIMDY (SEQ ID NO:5); (iv) HVR-L1 comprising RASQDVSX 1 AVA (SEQ ID NO:29), wherein X 1 is S or T; (v) HVR-L2 comprising SASX 1 LYS (SEQ ID NO:30), wherein X 1 is F or S; and (vi) HVR-L3 comprising QQAYX 1 X 2 X 3 X 4 T (SEQ ID NO:37), wherein X 1 is P, R or T; X 2 is A, I, S or T; X 3 is L, P or Q; X 4 is A, H, P or S. 2 - 100 . (canceled)
Assignees
Inventors
Classifications
Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues · CPC title
- C07K16/40Primary
against enzymes · CPC title
Stabilisation, fragmentation · CPC title
Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title
comprising antibodies · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2016355606A1 cover?
- The invention provides anti-PCSK9 antibodies, formulations, dosing regimens, and methods of using the same.
- Who is the assignee on this patent?
- Genentech Inc
- What technology area does this patent fall under?
- Primary CPC classification C07K16/40. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Thu Dec 08 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).